News
-
-
-
-
-
-
PRESS RELEASE
Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO
Catheter Precision, Inc. announced the conclusion of the patient follow-up phase for the VIVO European Registry. Data to be available Q4 2024, ongoing evaluations and studies for VIVO and LockeT -
-
-
-
PRESS RELEASE
Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024
Catheter Precision, Inc. reports 15% quarter-over-quarter growth with initial sales of LockeT recorded, generating total revenue of $94,840 for Q2 ending June 30, 2024